| ￥3500 | |
| Z05916-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | |
| Protein Construction |
|
|
| Purity | > 95% as determined by BisTris PAGE | |
| Endotoxin Level | Less than 1EU per μg by the LAL method. | |
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | |
| Expression System | E.coli | |
| Theoretical Molecular Weight | 19.6 kDa | |
| Apparent Molecular Weight | The protein has a predicted MW of 19.6 kDa same as Bis-Tris PAGE result. | |
| Formulation | Lyophilized from 0.22 μm filtered solution in 50mM Tris, 300mM NaCl (pH 7.2). | |
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | |
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized Human Trail, No Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for TRAIL/TNFRSF10, Human, hFc Tag with the EC50 of 9.8ng/ml determined by ELISA. »
Immobilized Human Trail, No Tag at 2 μg/ml(100 μl/well) on the plate. Dose response curve for TRAIL/TNFRSF10, Human, hFc Tag with the EC50 of 9.8ng/ml determined by ELISA. »
The purity of TRAIL/TNFRSF10, Human is greater than 95% as determined by SEC-HPLC. »
TRAIL/TNFRSF10, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
TRAIL/TNFRSF10, Human, His Tag immobilized on CM5 Chip can bind Human TRAIL, No Tag with an affinity constant of 0.57 nM as determined in SPR assay (Biacore T200). »
| Target Background | Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily that can initiate the apoptosis pathway by binding to its associated death receptors DR4 and DR5. The activation of the TRAIL pathway in inducing tumor-selective apoptosis leads to the development of TRAIL-based cancer therapies, which include recombinant forms of TRAIL, TRAIL receptor agonists, and other therapeutic agents. |
| Synonyms | Apo-2L; TRAIL; CD253; TNFSF10; Apo-2 ligand; APO2L; TL2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
